Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)224.19
  • Today's Change2.16 / 0.97%
  • Shares traded967.20k
  • 1 Year change+87.62%
  • Beta0.4317
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

  • Revenue in USD (TTM)770.23m
  • Net income in USD-277.50m
  • Incorporated2006
  • Employees1.02k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nuvalent Inc0.00-381.44m7.95bn218.00--8.80-----5.32-5.320.0011.700.00----0.00-35.18-25.32-37.61-26.51------------0.00-------106.59------
Praxis Precision Medicines Inc7.46m-273.04m8.76bn116.00--19.69--1,173.48-12.90-12.900.353316.230.0184----64,336.21-67.20-70.37-75.12-79.85-----3,658.53-6,809.15----0.00--249.53---48.30------
Arrowhead Pharmaceuticals Inc1.09bn202.27m8.77bn711.0040.6515.1433.918.041.541.547.904.140.8335--9.861,534,432.0017.84-25.9621.44-30.82----21.41-76.01--5.910.5068--23,258.1556.6399.73--13.66--
Charles River Lbrtrs ntrntl Inc4.02bn-83.48m9.14bn18.60k--2.6826.302.27-1.56-1.5680.1869.200.51868.235.41216,328.20-1.035.12-1.206.0134.6836.56-1.989.471.103.180.3880.00-1.929.09-97.83-47.2510.64--
Tempus AI Inc1.11bn-203.88m10.16bn2.40k--20.00--9.19-1.18-1.186.452.860.67959.295.15460,524.20-12.53-53.69-15.38-72.1061.7345.68-18.45-84.293.12-3.830.7104--30.3862.05-180.61--5.36--
BIO-TECHNE Corp1.22bn79.96m10.24bn3.10k129.015.0855.768.430.50760.50767.7412.900.46822.066.04392,121.603.087.623.278.1366.6067.496.5816.743.0856.920.114526.725.2310.55-56.35-20.37-9.74-4.36
Madrigal Pharmaceuticals Inc740.64m-289.13m11.09bn528.00--17.72--14.97-13.01-13.0133.3927.560.60820.900810.301,402,727.00-23.74-68.48-30.98-85.3295.25---39.04-876.553.26--0.3519-------24.69--106.52--
Summit Therapeutics Inc0.00-921.62m11.14bn159.00--57.96-----1.24-1.240.000.25830.00----0.00-241.08-78.31-287.72-86.84-------31,307.77----0.00------64.01---16.43--
Exelixis Inc2.29bn677.90m11.78bn1.15k18.505.4516.655.152.382.388.008.060.79133.197.901,994,959.0023.449.5127.0310.7796.6396.3229.6315.613.68--0.000.0018.4917.51150.8910.1817.25--
ICON PLC8.10bn599.48m11.80bn39.80k20.891.2611.941.467.407.40101.04122.250.4806--3.00193,379.503.563.704.334.4628.1529.007.407.41--5.940.2675--1.9924.1729.2616.1827.11--
Regencell Bioscience Holdings Ltd0.00-3.58m13.70bn12.00--2,819.75-----0.0073-0.00730.000.00980.00----0.00-50.50-53.93-53.75-65.67------------0.00------16.68--5.32--
Ionis Pharmaceuticals Inc966.96m-256.34m13.73bn1.07k--22.11--14.20-1.71-1.715.873.840.31630.605445.47904,542.60-8.39-11.71-10.45-13.7298.7898.42-26.51-44.152.78--0.7414---10.48-8.88-23.92--7.94--
Ascendis Pharma A/S (ADR)770.23m-277.50m13.76bn1.02k------17.87-4.56-4.5612.60-3.360.57510.30087.70757,357.90-20.72-45.75-109.98-79.5186.80---36.03-322.470.7256-1.781.27--36.3493.5921.47---22.67--
Medpace Holdings Inc2.53bn451.12m14.94bn6.20k34.6832.7031.175.9015.2915.2985.6816.221.24--7.24--22.1318.5255.4237.5330.0629.6017.8317.15--------19.9722.2711.5725.500.0102--
Revolution Medicines Inc0.00-960.98m18.70bn809.00--11.49-----5.18-5.180.008.420.00----0.00-47.87-28.38-52.53-30.68-------1,324.37----0.1384---100.00---37.52--31.83--
Data as of Feb 10 2026. Currency figures normalised to Ascendis Pharma A/S's reporting currency: US Dollar USD

Institutional shareholders

68.13%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 30 Sep 202510.28m16.86%
Westfield Capital Management Co. LPas of 30 Sep 20255.26m8.63%
Avoro Capital Advisor LLCas of 30 Sep 20255.11m8.38%
Janus Henderson Investors US LLCas of 30 Sep 20254.23m6.95%
Fidelity Management & Research Co. LLCas of 30 Sep 20254.12m6.76%
Artisan Partners LPas of 31 Dec 20253.23m5.29%
Capital Research & Management Co. (International Investors)as of 30 Sep 20253.06m5.02%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20252.67m4.37%
Massachusetts Financial Services Co.as of 31 Dec 20251.83m3.00%
Wellington Management Co. LLPas of 30 Sep 20251.75m2.87%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.